Online inquiry

IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10360MR)

This product GTTS-WQ10360MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10360MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7907MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ3356MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ14769MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ7877MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ379MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ11722MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ10624MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ8659MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW